# Wave Life Sciences to Present at Upcoming Investor Conferences

November 25, 2026

CAMBRIDGE, Mass., Nov. 25, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December.

**9th Annual Evercore Healthcare Conference**
Date: Wednesday, December 2, 2026
Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 11:15 a.m. ET

**Citi 2026 Global Healthcare Conference**
Date: Thursday, December 3, 2026
Details: Dr. Bolno will participate in an analyst-led fireside chat at 11:00 a.m. ET

Live webcasts of the presentations can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Replays of these presentations will be archived and available on the site for a limited time following the event.

**About Wave Life Sciences**
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s lead pipeline programs include obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008), as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

**Contact:**
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

**Investors:**
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

**Media**:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com